Gkos.K
GKOS.K operates in the Medical Equipment, Supplies & Distribution industry, providing healthcare services and equipment.
Business. GKOS.K operates in the Healthcare Services & Equipment industry, specifically within the Medical Equipment, Supplies & Distribution sector. The company generates revenue through a product-sale model, focusing on medical equipment and supplies. Headquarters location, operating segments, and geographic breakdowns are not specified in the available data. The company is listed under the ticker GKOS.K.
Analyst recommendations
16 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Glaukos Corp (GKOS.K) has recorded a major modification in its holder profile, marking the first analysis for this ticker. The most significant development is a substantial increase in share ownership by investor ID 587, whose position swelled from 123 shares to 34,133 shares as of March 31, 2026. This change was detected on June 20, 2026, and represents a shift in the investor's portfolio weight from a negligible 0.0000076% to 0.212%, with the holding's value rising from $13,242 to $3.67 million. This accumulation highlights a notable shift in capital allocation toward the company, despite the absence of prior data for delta computation. The magnitude of the increase—over 276 times the previous share count—suggests a deliberate entry or significant expansion by this specific investor. Given that Glaukos Corp currently has 32 top holders, this move adds to the diversity and depth of its shareholder base. The company's current structure includes one officer and is followed by five analysts, providing a baseline for market scrutiny. With no index memberships reported, the stock's visibility relies heavily on individual investor interest and analyst coverage. The recent activity by investor ID 587 may signal growing confidence in the company's prospects, warranting attention from other market participants. While no cross-source signals or sagas are available to provide additional context, the holder change stands as a primary indicator of shifting sentiment. Investors should monitor whether this accumulation is part of a broader trend among the 32 top holders or an isolated event. The financials and estimates associated with Glaukos Corp will be critical in assessing the long-term implications of this increased ownership.
Signals & dispatch
Composite-score breakdown
Synthesis
GKOS.K operates in the Healthcare Services & Equipment industry, specifically within the Medical Equipment, Supplies & Distribution sector. The company generates revenue through a product-sale model, focusing on medical equipment and supplies. Headquarters location, operating segments, and geographic breakdowns are not specified in the available data. The company is listed under the ticker GKOS.K.
GKOS.K has a market price of $134.92, resulting in a market capitalization of $7.92 billion. The company's price-to-book ratio is 12.08, and its price-to-tangible-book ratio is also 12.08, indicating a premium valuation relative to its book value. The enterprise value to EBITDA ratio is negative at -39.59, reflecting the company's current operating losses. The enterprise value to revenue ratio is 15.57, suggesting a moderate valuation relative to its revenue.
In terms of profitability, GKOS.K has a return on equity of -28.6% and a return on assets of -21.01%, both of which are significantly below industry norms and indicate poor performance. The company's gross profit margin is 78.0%, which is relatively high, but this is offset by a negative operating margin of -3.9% and a net margin of -3.7%. These metrics suggest that while the company is generating substantial gross profits, it is unable to convert these into operating or net profits.
Geographically, GKOS.K's revenue is concentrated in the United States, with no significant international exposure disclosed in the available data. The company's revenue is primarily derived from its core healthcare services and equipment business, with no material diversification into other segments.
Looking at the company's growth trajectory, GKOS.K has reported a revenue of $507.44 million in the latest period. However, the company is currently experiencing negative operating and net income, with operating income at -$19.96 million and net income at -$187.69 million. The company's free cash flow is also negative at -$171.39 million, indicating that it is not generating sufficient cash to fund its operations and capital expenditures. The capital expenditure for the period is -$24.27 million, suggesting that the company is investing in its operations.
In terms of risk, GKOS.K has a low liquidity risk, with a current ratio of 4.69, indicating that it has sufficient current assets to cover its current liabilities. The company's debt-to-equity ratio is 0.11, suggesting a conservative capital structure with minimal leverage. The risk assessment indicates a low dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's liquidity position is supported by $90.81 million in cash and equivalents.
Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's operating cash flow is negative at -$14.79 million, which is consistent with its negative net income. The company's total assets are $893.49 million, and its total liabilities are $237.33 million, resulting in a total equity of $656.16 million. The company's long-term debt is $69.46 million, which is relatively low compared to its total equity.
Glaukos Corp (GKOS.K) has recorded a major modification in its holder profile, marking the first analysis for this ticker. The most significant development is a substantial increase in share ownership by investor ID 587, whose position swelled from 123 shares to 34,133 shares as of March 31, 2026. This change was detected on June 20, 2026, and represents a shift in the investor's portfolio weight from a negligible 0.0000076% to 0.212%, with the holding's value rising from $13,242 to $3.67 million. This accumulation highlights a notable shift in capital allocation toward the company, despite the absence of prior data for delta computation. The magnitude of the increase—over 276 times the previous share count—suggests a deliberate entry or significant expansion by this specific investor. Given that Glaukos Corp currently has 32 top holders, this move adds to the diversity and depth of its shareholder base. The company's current structure includes one officer and is followed by five analysts, providing a baseline for market scrutiny. With no index memberships reported, the stock's visibility relies heavily on individual investor interest and analyst coverage. The recent activity by investor ID 587 may signal growing confidence in the company's prospects, warranting attention from other market participants. While no cross-source signals or sagas are available to provide additional context, the holder change stands as a primary indicator of shifting sentiment. Investors should monitor whether this accumulation is part of a broader trend among the 32 top holders or an isolated event. The financials and estimates associated with Glaukos Corp will be critical in assessing the long-term implications of this increased ownership.
- GKOS.K has a high price-to-book ratio of 12.08, indicating a premium valuation relative to its book value.
- The company's return on equity is -28.6%, and its return on assets is -21.01%, both of which are significantly below industry norms.
- GKOS.K has a low liquidity risk, with a current ratio of 4.69, indicating that it has sufficient current assets to cover its current liabilities.
- The company's debt-to-equity ratio is 0.11, suggesting a conservative capital structure with minimal leverage.
- GKOS.K has a low dilution risk, with no immediate filing-based liquidity or dilution flags detected.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,55 |
| Revenue | —no estimate | —no estimate | 627,7M UNKNOWN ERROR IN UNIVERSE PROCESSING |
| Operating income | —no estimate | —no estimate | -35,9M UNKNOWN ERROR IN UNIVERSE PROCESSING |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director · Stock Option (Right to Buy) → Common StockAcquired 2 987 @ $53,57grant · 2026-05-28
- Director · Stock Option (Right to Buy) → Common StockAcquired 2 987 @ $53,57grant · 2026-05-28
- Director · Stock Option (Right to Buy) → Common StockAcquired 2 987 @ $53,57grant · 2026-05-28
- Director · Stock Option (Right to Buy) → Common StockAcquired 2 987 @ $53,57grant · 2026-05-28
- Director · Stock Option (Right to Buy) → Common StockAcquired 2 987 @ $53,57grant · 2026-05-28
- Director · Stock Option (Right to Buy) → Common StockAcquired 2 987 @ $53,57grant · 2026-05-28
- Director · Stock Option (Right to Buy) → Common StockAcquired 2 987 @ $53,57grant · 2026-05-28
- Director · Stock Option (Right to Buy) → Common StockDisposed 15 000 @ $24,69exercise · 2026-05-26
- Director · Stock Option (Right to Buy) → Common StockDisposed 5 000 @ $24,69exercise · 2026-05-14
- Director · Stock Option (Right to Buy) → Common StockDisposed 5 000 @ $24,69exercise · 2026-05-11
- SVP & CHIEF FINANCIAL OFFICER · Stock Option (Right to Buy) → Common StockDisposed 10 000 @ $38,68exercise · 2026-04-30
- SVP & CHIEF FINANCIAL OFFICER · Stock Option (Right to Buy) → Common StockAcquired 8 228 @ $55,18grant · 2026-03-25
- Director, CHAIRMAN & CEO · Stock Option (Right to Buy) → Common StockAcquired 18 933 @ $55,18grant · 2026-03-25
- Director, CHAIRMAN & CEO · Stock Option (Right to Buy) → Common StockAcquired 110 254 @ $48,46grant · 2026-03-25
- Director, CHAIRMAN & CEO · Stock Option (Right to Buy) → Common StockAcquired 98 474 @ $109,60grant · 2026-03-25
- PRESIDENT & COO · Stock Option (Right to Buy) → Common StockAcquired 21 955 @ $55,18grant · 2026-03-25
- SVP & CHIEF FINANCIAL OFFICER · Stock Option (Right to Buy) → Common StockAcquired 20 515 @ $109,60grant · 2026-03-25
- PRESIDENT & COO · Stock Option (Right to Buy) → Common StockAcquired 16 462 @ $55,18grant · 2026-03-25
- PRESIDENT & COO · Stock Option (Right to Buy) → Common StockAcquired 36 751 @ $48,46grant · 2026-03-25
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- GKOS.K Market data — financials · 2026-05-28
- Glaukos Corp Market data — analyst estimates · 2026-05-28
Ownership & reference
Top holders
- Institutional Investor · as of 2026-03-310,29 %$576M
- Investment Managers · as of 2026-03-310,05 %$158M
- Institutional Investor · as of 2026-03-310,04 %$173M
- Investment Managers · as of 2026-03-310,04 %$52M
- Investment Managers · as of 2026-03-310,02 %$148M
- Investment Managers · as of 2026-03-310,02 %$30M
- Funds · as of 2026-03-310,02 %$98M
- Investment Managers · as of 2024-12-310,01 %$47M
- Investment Managers · as of 2026-03-310,01 %$77M
- Investment Managers · as of 2025-12-310,01 %$680M
- Investment Managers · as of 2026-03-310,01 %$40M
- Investment Managers · as of 2026-03-310,01 %$146M
- Investment Managers · as of 2026-03-310,01 %$62M
- Investment Managers · as of 2026-03-310,01 %$235M
- Investment Managers · as of 2026-03-310,01 %$42M
- Institutional Investor · as of 2026-03-310,01 %$37M
- Investment Managers · as of 2026-03-310,01 %$8M
- Investment Managers · as of 2026-03-310,00 %$21M
- Investment Managers · as of 2026-03-310,00 %$73M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$5M
- Brokerage Firms · as of 2026-03-310,00 %$10M
- Investment Managers · as of 2026-03-310,00 %$16M
- Investment Managers · as of 2026-03-310,00 %$4M
- Institutional Investor · as of 2026-03-310,00 %$33M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$2M
- Brokerage Firms · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2024-06-300,00 %$6M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Thomas William BurnsChairman of the Board, Chief Executive Officer
Insider activity
- CHIEF DEVELOPMENT OFFICER · Common StockSold 1 537 @ $130,68$201K · 2026-06-16
- Director · Common StockOther 1 878 · 2026-05-28
- Director · Common StockOther 1 878 · 2026-05-28
- Director · Common StockOther 1 878 · 2026-05-28
- Director · Common StockOther 1 878 · 2026-05-28
- Director · Common StockOther 1 878 · 2026-05-28
- Director · Common StockOther 1 878 · 2026-05-28
- Director · Common StockOther 1 878 · 2026-05-28
- Director · Common StockOther 15 000 @ $24,69$370K · 2026-05-26
- Director · Common StockOther 5 000 @ $24,69$123K · 2026-05-14
- Director · Common StockSold 5 000 @ $140,76$704K · 2026-05-14
- Director · Common StockSold 5 000 @ $135,00$675K · 2026-05-11
- Director · Common StockOther 5 000 @ $24,69$123K · 2026-05-11
- PRESIDENT & COO · Common StockSold 19 573 @ $143,54$2,8M · 2026-05-01
- Director · Common StockSold 1 700 @ $143,35$244K · 2026-05-01
- SVP & CHIEF FINANCIAL OFFICER · Common StockOther 10 000 @ $38,68$387K · 2026-04-30
- SVP & CHIEF FINANCIAL OFFICER · Common StockSold 10 000 @ $140,00$1,4M · 2026-04-30
- CHIEF DEVELOPMENT OFFICER · Common StockSold 210 @ $117,45$25K · 2026-04-10
- CHIEF DEVELOPMENT OFFICER · Common StockSold 1 237 @ $116,72$144K · 2026-04-10
- CHIEF DEVELOPMENT OFFICER · Common StockSold 614 @ $119,35$73K · 2026-04-10
- CHIEF DEVELOPMENT OFFICER · Common StockSold 32 @ $120,23$4K · 2026-04-10
- Director, CHAIRMAN & CEO · Common StockOther 7 468 @ $109,60$818K · 2026-04-02
- CHIEF DEVELOPMENT OFFICER · Common StockOther 1 831 @ $109,60$201K · 2026-04-02
- SVP & CHIEF FINANCIAL OFFICER · Common StockOther 1 589 @ $109,60$174K · 2026-04-02
- PRESIDENT & COO · Common StockOther 3 169 @ $109,60$347K · 2026-04-02
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -14.4%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 14.2%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -18.4%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): -2.3%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -28.2%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 75.9%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -63.1%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 32.3%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -8.3%Derived (calculated)
- Net margin (FY 2025-12-31): -37.0%Derived (calculated)
- Gross margin (FY 2025-12-31): 55.7%Derived (calculated)
- Return on equity (FY 2025-12-31): -28.6%Derived (calculated)
- Return on assets (FY 2025-12-31): -21.0%Derived (calculated)
- Current ratio (FY 2025-12-31): 4.69xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.36xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 21.7%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -46.5%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 18.9%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -18.4%Derived (calculated)
- Total liabilities (annual): USD 237.33MSEC XBRL filing
- Operating cash flow (annual): USD -14.79MSEC XBRL filing
- Cash & equivalents (annual): USD 90.81MSEC XBRL filing
- Total operating expenses (annual): USD 482.36MSEC XBRL filing
- Gross profit (annual): USD 282.76MSEC XBRL filing